How are you clinically incorporating the data presented from RT Charm at ASTRO 2024?

This is an appropriate question with the presentation of RT CHARM at ASTRO a few weeks ago. We have been utilizing hypofractionated NON-reconstruction PMRT and regional nodal breast RT for years in my practice given our large geographic catchment area. As a general rule, I feel it's always best practice to await the publication of trial results before adopting data that is practice-changing, as more than once the outcomes seen in the abstract or presentation at a meeting take years to be publish...

Yes, routinely offering hypofractionation with RT CHARM and FABREC supporting it.

It’s becoming increasingly difficult to rationalize conventionally-fractionated radiotherapy for breast cancer.

Additional information on the safety of hypofractionated nodal radiotherapy recently emerged. The 2024 ESMO presentation 2310 of HypoG-01 solidifies the use of nodal hypofractionation as a safe method to treat the breast or chest wall and nodal basins. A broad range of stages, pT1-3 & pN0-3, HER2, receptor status, and grades means that the applicable population is large. Neoadjuvant therapy was allowed. No differences appeared comparing 40/15 to 50/25 with the option of a single boost site. The ...

RT CHARM is written and being submitted for publication.